R. Bhardwaj

P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects

V. Coric, R. Bertz, Jennifer Madonia, 2022, Clinical pharmacology in drug development.

Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants

R. Bertz, R. Croop, J. Stringfellow, 2023, Headache.

Optimal ADME Properties for Clinical Candidate and Investigational New Drug (IND) Package

G. Chandrasena, Rajinder Bhardwaj, R. Bhardwaj, 2012 .

DELINEATION OF HPEPT1 MEDIATED UPTAKE AND TRANSPORT OF SUBSTRATES WITH VARYING TRANSPORTER AFFINITIES UTILIZING STABLY TRANSFECTED HPEPT1/MDCK CLONES AND CACO-2 CELLS

P. Sinko, O. Gudmundsson, D. Herrera-Ruiz, 2005 .

A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants

V. Coric, R. Bertz, R. Croop, 2023, Cephalalgia : an international journal of headache.

Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open‐Label, Single‐Dose, Parallel‐Group Study

V. Coric, R. Bertz, R. Croop, 2023, Clinical pharmacology in drug development.

The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Study

R. Croop, Beth A Morris, R. Bhardwaj, 2023, Clinical pharmacology in drug development.